新的研究强调了当使用CAR - t细胞作为标准治疗时，淋巴瘤治疗成功

嵌合抗原受体T细胞疗法或汽车T被评为美国临床肿瘤学会年度2017年的进展。FDA去年批准了两辆汽车T产品，用于治疗成人大B细胞淋巴瘤，基于临床试验中的特殊患者结果。现在，其中一个产品的后续研究表明，当用作护理标准时它与临床试验结果相匹配。

Moffitt癌症中心与16个学术癌症中心合作，分析了274的现实世界数据耐心与yescarta（轴突Ciloleucel）商业化，这是两辆汽车T产品之一，现在是弥漫性大B细胞淋巴瘤（DLBCL）患者的护理标准，他们没有反应两个或多个疗法。然后研究人员将这些数字与枢轴祖马-1试验结果进行了比较，其中包括101名患者。最终的比较结果，该结果于12月1日星期六在美国血液学会年会，显示Yescarta诱导DLBCL患者的剩余，作为护理标准。

“现在，Yescarta是大B细胞淋巴瘤患者的标准护理，已经进展后的两个之前的线治疗, we wanted to compare the standard of care outcomes, including response rates and onset of side effects, with the results from the clinical trial that led to the therapy's approval," said Michael Jain, M.D., Ph.D., co-first author of the study and assistant member of Moffitt's Blood and Marrow Transplant and Cellular Immunotherapy. "Our results showed that patient response rates, and the toxicity profile, were consistent with the ZUMA-1 trial results."

现实世界数据显示，在四个月的中位随访中，81％的护理标准患者患有58％的治疗，显示没有可检测的癌症。在Yescarta的FDA批准时（2017年10月），Zuma-1临床试验的结果表明，72％的患者对治疗的患者患者患有51％，其中没有可检测的癌症留下的中位随访7.9个月。

"This study echoes the early results in the ZUMA-1 clinical trial and provides further evidences that CAR T-cell therapy, such as Yescarta, is a feasible option for patients who would otherwise have no viable treatments options," said Frederick Locke, M.D., associate member and vice chair of the Blood and Marrow Transplant and Cellular Immunotherapy Department, and co-leader of the Immunology Program at Moffitt., who served as co-senior author of the study.

---

---